These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Cotonat T; Quiroga JA; López-Alcorocho JM; Clouet R; Pardo M; Manzarbeitia F; Carreño V Hepatology; 2000 Feb; 31(2):502-6. PubMed ID: 10655277 [TBL] [Abstract][Full Text] [Related]
9. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population? Fabrizi F; Messa P Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524 [TBL] [Abstract][Full Text] [Related]
10. Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection. Sagir A; Heintges T; Akyazi Z; Oette M; Erhardt A; Häussinger D Liver Int; 2007 Sep; 27(7):954-9. PubMed ID: 17696934 [TBL] [Abstract][Full Text] [Related]
11. [Retreatment of patients with chronic hepatitis C]. Ostojić R Acta Med Croatica; 2005; 59(5):447-51. PubMed ID: 16381242 [TBL] [Abstract][Full Text] [Related]
12. Current antiviral combination therapy for chronic hepatitis C patients who failed to interferon alfa-based treatment. Trapero-Marugán M; Mendoza J; Moreno Monteagudo JA; Chaparro M; García-Buey L; González-Moreno L; Borque MJ; Moreno-Otero R J Clin Pharm Ther; 2011 Dec; 36(6):695-703. PubMed ID: 21175705 [TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group. Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370 [TBL] [Abstract][Full Text] [Related]
14. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs. Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650 [TBL] [Abstract][Full Text] [Related]
15. Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study. Seo KI; Yun BC; Li WJ; Lee SU; Han BH; Park ET Clin Mol Hepatol; 2017 Mar; 23(1):74-79. PubMed ID: 28259115 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of interferon retreatment on interferon-resistant patients with chronic hepatitis C. Egusa K; Kondo J Acta Med Okayama; 2003 Jun; 57(3):151-8. PubMed ID: 12908013 [TBL] [Abstract][Full Text] [Related]
17. Retreatment with peginterferon and ribavirin in chronic hepatitis C. Jo YM; Lee SW; Han SY; Baek YH; Kim SY; Kim WJ; Ahn JH; Lee JY World J Gastroenterol; 2015 Feb; 21(6):1994-9. PubMed ID: 25684969 [TBL] [Abstract][Full Text] [Related]
19. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin. Abbas Z; Hamid SS; Tabassum S; Jafri W J Pak Med Assoc; 2004 Nov; 54(11):571-4. PubMed ID: 15623184 [TBL] [Abstract][Full Text] [Related]
20. Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon. Chapman BA; Stace NH; Edgar CL; Bartlett SE; Frampton CM; Scahill SL; Jennings LC N Z Med J; 2001 Mar; 114(1128):103-4. PubMed ID: 11346153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]